Immunotherapy of insulin-dependent diabetes mellitus

Current Opinion in Immunology

Volumn 14, Issue 5, 2002, Pages 652-659

  Sykes, Megan ^a  

^a Transplantation Biology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 3; T LYMPHOCYTE RECEPTOR;

ALLOTRANSPLANTATION; CLINICAL TRIAL; GRAFT REJECTION; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LANGERHANS CELL; NONHUMAN; PANCREAS; REVIEW; T LYMPHOCYTE;

EID: 0036774891     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00375-8     Document Type: Review

References (53)

1. Skyler J., Rabinovitch A. Effects of cyclosporine in recent onset type 1 diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J Diabetes. 6:1992;77-88.
2. Parving H.-H., Tarnow L., Nielsen F., Rossing P., Mandrup-Poulsen T., Osterby R., Nerup J. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care. 22:1999;478-483.
3. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 19:2001;225-252.
4. Bach J.-F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol. 19:2001;131-161.
5. Smith J.A., Bluestone J.A. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol. 9:1997;648-654.
6. Sloan-Lancaster J., Allen P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol. 14:1996;1-27.
7. Chatenoud L., Thervet E., Primo J., Bach J.-F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA. 91:1994;123-127.
8. Chatenoud L., Primo J., Bach J.-F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol. 158:1997;2947-2954.
9. Alegre M.L., Peterson L.J., Xu D., Sattar H.A., Jeyarajah D.R., Kowalkowski K., Thistlethwaite J.R., Zivin R.A., Jolliffe L., Bluestone J.A. A non-activating humanized anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 57:1994;1537-1543.
10. Alegre M.L., Tso J.Y., Sattar H.A., Smith J., Desalle R., Cole M., Bluestone J.A. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 155:1995;1544-1555.
11. Woodle E.S., Bluestone J.A., Zivin R.A., Jolliffe L.K., Auger J., Xu D., Thistlethwaite J.R. Humanized, nonmitogenic OKT3 antibody, huOKT3γ1(Ala-Ala): initial clinical experience. Transplant Proc. 30:1998;1369-1370.
12. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., Peace D., Jolliffe L.K., Haverty T., Bluestone J.A., Thistlewaite J. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 68:1999;608-616.
13. Smith J.A., Tso J.Y., Clark M.R., Cole M.S., Bluestone J.A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med. 185:1997;1413-1422.
14. Smith J.A., Tang Q., Bluestone J.A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol. 160:1998;4841-4849.
15. Tang Q., Subudhi S.K., Henriksen K.J., Long C.G., Vives F., Bluestone J.A. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol. 168:2002;4480-4487.
16. Shapiro A.M.J., Lakey J.R.T., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 343:2000;289-290.
17. Malek T.R., Porter B.O., Codias E.K., Scibelli P., Yu A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol. 164:2000;2905-2914.
18. Wolf M., Schimpl A., Hunig T. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol. 31:2001;1637-1645.
19. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
20. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 346:2002;1692-1698. Demonstrates that anti-CD3 mAb therapy in new-onset diabetic patients can moderate the ongoing anti-islet autoimmunity and preserve residual β cell function, resulting in a decreased need for injected insulin.
21. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., Ten S., Sanz M., Exley M., Wilson B., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 109:2002;131-140.
22. Waldmann H., Cobbold S. Regulating the immune response to transplants: a role for CD4+ regulatory cells? Immunity. 14:2001;399-406.
23. Tisch R., Wang B., Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at the late stages of disease is epitope dependent. J Immunol. 163:1999;1178-1187.
24. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med. 6:2000;1176-1182.
25. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., Tsai M., Galli S.J., Steinman L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol. 2:2001;216-222.
26. Ehl S., Hombach J., Aichele P., Rulicke T., Odermatt B., Hengartner H., Zinkernagel R., Pircher H. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med. 187:1998;763-774.
27. Moriyama H., Wen L., Abiru N., Liu E., Yu L., Miao D., Gianani R., Wong F.S., Eisenbarth G.S. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci USA. 99:2002;5539-5544.
28. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediate diseases: immplications for immunotherapy. Nat Rev Immunol. 2:2002;85-95.
29. Elias D., Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet. 343:1994;704-706.
30. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet. 358:2001;1749-1753.
31. Pozzilli P., Pitocco D., Visalli N., Cavallo M.G., Buzzetti R., Crino A., Spera S., Suraci C., Multari G., Cervoni M., et al. No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII). Diabetologia. 43:2000;1000-1004.
32. Chaillous L., Lefevre H., Thivolet C., Boitard C., Lahlou N., Atlan Gepner C., Bouhanick B., Mogenet A., Nicolino M., Carel J., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet. 356:2000;545-549.
33. Diabetes Prevention Trial-Type 1 (DPT) Study Group . Effects of parenteral insulin in relatives at high risk of type 1 diabetes mellitus. N Engl J Med. 346:2002;1685-1691. A large-scale controlled clinical trial demonstrating that parenteral administration of insulin to individuals considered to be at high risk for developing diabetes did not delay or prevent the development of type 1 diabetes.
34. Muir A., Peck A., Salzer M.C., Song Y.H., Cornelius J., Luchetta R., Krischer J., Maclaren N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest. 95:1995;628-634.
35. Ramiya V.K., Shang X.Z., Pharis P.G., Wasserfall C.H., Stabler T.V., Muir A.B., Schatz D.A., Maclaren N.K. Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun. 9:1996;349-356.
36. Reijonen H., Novak E.J., Kochik S., Heninger A., Liu A.W., Kwok W.W., Nepom G.T. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes. 51:2002;1375-1382. Soluble HLA-DR401 and -DR404 tetramers presenting a human GAD65 peptide detected GAD65-specific T cells in all type 1 diabetic patients examined and in some at-risk subjects, but not in normal controls. Phenotyping of antigen-specific T cells utilizing HLA class II tetramers provides new technology that will greatly aid in characterizing autoimmune T cell responses to immunotherapy.
37. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B.J., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med. 6:2000;1167-1175.
38. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
39. Davenport M.P., Fazou C., McMichael A.J., Callan M.R.C. Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J Immunol. 168:2002;3309-3317.
40. O'Herrin S.M., Slansky J.E., Tang Q., Markiewicz M.A., Gajewski T.F., Pardoll D.M., Schneck J.P., Bluestone J.A. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 167:2001;2555-2560.
41. Casares S., Bona C.A., Brumeanu T.-D. Enzymatically mediated engineering of multivalent MHC class II-peptide chimeras. Protein Eng. 14:2001;195-200.
42. Sharma S.D., Nag B., Su X.-M., Green D., Spack E., Clark B.R., Sriram S. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA. 88:1991;11465-11469.
43. Spack E.G., McCutcheon M., Corbelletta N., Nag B., Passmore D., Sharma S.D. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes. J Autoimmun. 8:1995;787-807.
44. Burrows G.G., Adlard K.L., Bebojjj B.F. Jr, Chang J.W., Tenditnyy K., Vandenbark A.A., Offner H. Regulation of encephalitogenic T cells with recombinant TCR ligands. J Immunol. 164:2000;6366-6371.
45. Hamad A.R.A., O'Herrin S.M., Lebowitz M.S., Srikrishnan A., Bieler J., Schneck J., Pardoll D. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J Exp Med. 188:1998;1633-1640.
46. Casares S., Zong C.S., Radu D.L., Miller A., Bona C.A., Brumeanu T.-D. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med. 190:1999;543-553.
47. Cochran J.R., Cameron T.O., Stern L.J. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity. 12:2000;241-250.
48. Appel H., Seth N.P., Gauthier L., Wucherpfennig K.W. Anergy induction by dimeric TCR ligands. J Immunol. 166:2001;5279-5285.
49. Zuo L., Cullen C.M., DeLay M.L., Thornton S., Myers L.K., Rosloniec E.F., Boivin G.P., Hirsch R. A single-chain class II MHC-IgG3 fusion protein inhibits autoimmune arthritis by induction of antigen-specific hyporesponsiveness. J Immunol. 168:2002;2554-2559.
50. Casares S., Hurtado A., McEvoy R.C., Sarukhan A., von Boehmer H., Brumeanu T.-D. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol. 3:2002;383-391. Demonstration that peptide-MHC complexes can be used for effective immunotherapy in vivo in a transgenic model of spontaneous autoimmune diabetes. Protection appears to be provided by the induction of IL-10-producing T cells.
51. Judkowski V., Pinilla C., Schroder K., Tucker L., Sarvetnick N., Wilson D.B. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol. 166:2001;908-917.
52. Wong F.S., Karttunen J., Dumont C., Wen L., Visintin I., Pilip I.M., Shastri N., Pamer E.G., Janeway C.A. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med. 5:1999;1026-1031.
53. Amrani A., Verdaguer J., Serra P., Tafuro S., Tan R., Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature. 406:2000;739-742.